A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema or persistent active neovascularisation...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-003165-13

A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema or persistent active neovascularisation following lasercoagulation

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary objectives: - For Group A (persitient macular edema): To investigate the change in macular edema measured with standard optical coherence tomography (OCT) and the absolute change in visual acuity following intravitreal administered injections of Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema following grid lasercoagulation. - For Group B (persistent neovascularisation):∑ For Group B (persistent neovascularisation): To investigate the change of neovascularisation and vitreous hemorrhage following intravitreal administered injections of Bevacizumab (Avastin®) compared with non-treatment control as assessed by fundus photography and fluorescence angiography and the absolute change in visual acuity.


Critère d'inclusion

  • persistent diabetic macular edema or persistent active neovascularisation following lasercoagulation

Liens